A study published in the American Journal of Ophthalmology suggests that the use of SGLT2 inhibitors in diabetes is linked to ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...

The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 inhibitor medication had a lower risk of a subsequent stroke, heart attack or death ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

SGLT2 diabetes meds like Jardiance or Farxiga do the same, and also decrease risk of a follow-up stroke MONDAY, Nov. 11, 2024 ...

Stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death, according to a preliminary study being presented at the American Heart Association's annual Scientific Sessions, set ...

Stroke was the fourth leading cause of death in the US last year, accounting for 162,600 deaths, according to preliminary data.

The medications include GLP-1 drugs such as Ozempic from Novo Nordisk and Trulicity from Eli Lilly, and SGLT2 drugs such as Jardiance from Boehringer Ingelheim and Eli Lilly and Farxiga from ...